Smoking is indeed one of the vices that is so difficult to stop once you are hooked up with it. There are many warnings issued in four corners of the world about the myriad of bad effects and diseases it may bring.
According to cdc.gov there are 480,000 recorded deaths annually in the United States. The source added that in 2013, 18 of every 100 American adults aged 18 years and above (17.8%) smoke cigarettes and over 16 million Americans have a smoking-related disease.
If you are smoker or a relative of a smoker this write-up will certainly be interesting to you as there is a new research that discovered that a certain anti-smoking medication Chantix can boost the probability that a cigarette smoker who finds it difficult to stop will gradually cut back on his habit.
The people who initiated the study discerned that smokers who used varenicline were able to reduce their smoking, and majority of them eventually ended their smoking habit compared with those who are taking medications with placebo effect.
Pfizer Inc. funded the study and manufactures the Chantix (varenicline). The study has been published by JAMA.
The intake of varenicline gives rise to helping smokers to stop or cut down on their smoking habit by virtue of making cigarette smoking less appealing.
The smokers who are under the treatment ingests two pills per day will translate to US$280 per month and patients are recommended to use the medication for 12 to 24 weeks.
A professor of community health sciences at Boston University School of Public Health, Dr. Michael Siegel, quipped that, “The main contribution of this study is that it demonstrates that for patients who are not ready to quit right away, the use of Chantix could be helpful in getting them to cut down, and then, eventually, to making a quit attempt.”
The researchers aimed at a certain type of smokers which are those who are not ready to stop their smoking habit in the next month but are reduce their smoking and quit after three months.
The lead author of the study and a professor of medicine at the Mayo Clinic in Rochester, Dr. Jon Ebbert stated that research is divided over whether taking the treatment is a plausible option as opposed to totally stopping from the habit. The U.S. health guidelines favors quitting from the vice as soon as possible.
The patients were given the tasks to meet particular objectives like decrease smoking by 50% at the end of four weeks and by 75% at the end of eight weeks. The final target is to completely stop smoking at the end of 12 weeks.
After four weeks, 47.1% of a group that is under verinicline treatment decreased their smoking by half, whereas 31.1% a group that were under placebo treatment reduced their smoking by half.
However, the U.S. Food and Drug Administration stated that verinicline comes with black box warning that it may seriously contribute to depression or even suicide. Other possible behavior changes like becoming hostile and agitated may be experienced by people who will use the verinicline.